Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

ET-01 in Subjects With Lateral Canthal Lines, LCL-210

ClinicalTrials.gov ID: NCT04985916

Public ClinicalTrials.gov record NCT04985916. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Clinical Trial to Evaluate ET-01 in Subjects With Lateral Canthal Lines

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

Study identification

NCT ID
NCT04985916
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Eirion Therapeutics Inc.
Industry
Enrollment
280 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
25 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 19, 2021 (Actual)
Primary completion
Feb 8, 2024 (Actual)
Completion
Feb 8, 2024 (Actual)
Last update posted
Dec 9, 2024

2021 – 2024

United States locations

U.S. sites
19
U.S. states
14
U.S. cities
19
Facility City State ZIP Site status
Eirion Research Site Scottsdale Arizona 85255 —
Eirion Research Site San Diego California 92121 —
Eirion Research Site Aventura Florida 33180 —
Eirion Research Site Boca Raton Florida 33486 —
Eirion Research Site Miami Florida 33137 —
Eirion Research Site West Palm Beach Florida 33401 —
Eirion Research Site Chicago Illinois 60654 —
Eirion Research Site Louisville Kentucky 40241 —
Eirion Research Site New Orleans Louisiana 70124 —
Eirion Research Site Glenn Dale Maryland 20769 —
Eirion Research Site Clinton Township Michigan 48038 —
Eirion Research Site New Brighton Minnesota 55112 —
Eirion Research Site New York New York 10075 —
Eirion Research Site Exton Pennsylvania 19341 —
Eirion Research Site Newtown Square Pennsylvania 19073 —
Eirion Research Site Greenville South Carolina 29615 —
Eirion Research Site Houston Texas 77056 —
Eirion Research Site Plano Texas 75093 —
Eirion Research Site Norfolk Virginia 23502 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04985916, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 9, 2024 · Synced Oct 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04985916 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →